Neonatal Screening: Cost-utility Analysis for Galactosemia
Abstract
Background: Galactosemia is a congenital metabolic disorder that can damage the health of a newborn. Screening is an important step to prevent and treat this condition. Due to increasing health care costs and limited financial resources of health systems, the most suitable economic analysis tool should be applied. The aim of this study was to analyze the cost-utility of neonatal screening program for diagnosing galactosemia in Fars province, Iran.
Methods: In this cross-sectional study and cost-utility analysis in the cost of screening for galactosemia and its financial effects, decision tree model and society’s viewpoint were used. The population of study was 81837 infants referred to Neonatal Screening Laboratory (Nader Kazemi Clinic) affiliated to Shiraz University of Medical Sciences (SUMS), Iran, in 2010. Quality of life in two groups of patients was evaluated by using the time trade-off. The best intervention option was selected by using the Incremental Cost-effectiveness Ratio.
Results: The estimated cost of diagnosed through screening and without screening were 43519911 and 130011168 Iranian Rails (4222.00 $ and 12615.00 $), respectively. Therefore, there was a saving of 201443240.99 Iranian Rails (19641.00 $), for each patient annually.
Conclusion: The screening program can improve both the qualitative and quantitative lifestyle of people and increase savings in health care system. Policymakers could use the results to design new policies based on the necessity of screening.
Hajizade M (2008). Health Economic. First ed. Tehran: Jamenegar publication. Tehran.
Report by the Secretariat (2005). Control of genetic diseases. World Health Organization. http://apps.who.int/iris/bitstream/10665/20404/1/B116_3-en.pdf?ua=1.
Ficicioglu C, Thomas N, Yager C, Gallagher PR, Hussa C, Mattie A, Day-Salvatore DL, Forbes BJ (2008). Duarte (DG) galactosemia: A pilot study of biochemical and neurodevelopmental assessment in children detected by new-born screening. Mol Genet Metab, 95 (4): 206-12.
Mirzajani F, Mirfakhraei R, Saki S, Houshman M, Naghibzadeh N, Nabati F, Talachian E (2005). Biochemical diagnosis and identification of common mutations in Galactosemia. Quarterly J Rehab, 6 (1): 19-22.
Vakili R, Rasooli Sh (2002). Glucose-Galactose Malabsorption as a Rare Cause of Diarrhea in Newborn Period. Iran J Pediatr, 12 (4): 20-22.
Shield JP, Wadsworth EJ, MacDonald A, Stephenson A, Tyfield L, Holton JB, Marlow N (2000). The relationship of genotype to cognitive outcome in galactosaemia. Arch Dis Child, 83 (3): 248-50.
Senemar S, Ganjekarimi A, Senemar S, Tarami B, Bazrgar M (2011). The prevalence and clinical study of galactosemia disease in a pilot screening program of neonates, southern iran. Iran J Public Health, 40 (4): 99-104.
Wang BB, Xu YK, Ng WG, Wong LJ (1998). Molecular and biochemical basis of galactosemia. Mol Genet Metab, 63 (4): 263-69.
Elsas LJ, Lai K (1998). The molecular biology of galactosemia. Genet Med, 1 (1): 40-8.
Estrada SC, Canson DM, Silao CL (2013). Mutational Analysis of the GALT Gene in Filipino Patients. Kobe J Med Sci, 59 (3): E106 -11.
Takci S, Kadayifcilar S, aCoskun T, Yigit S, Hismi B (2012). A Rare Galactosemia Complication: Vitreous Hemorrhage. JIMD Rep, 5: 89-93.
Najafi M, Khodadad A, Khatami GR (2005). Cerebral edema: a rare complication in Galactosemia. Med J Islam Repub Iran, 18 (4): 371-73.
van Erven B, Gubbels CS, van Golde RJ, Dunselman GA, Derhaag JG, de Wert G, Geraedts JP, Bosch AM, Treacy EP, Welt CK, Berry GT, Rubio-Gozalbo ME (2013). Fertility preservation in female classic galactosemia patients. Orphanet J Rare Dis, 8: 107.
Jensen UG, Brandt NJ, Christensen E, Skovby F, Nørgaard-Pedersen B, Simonsen H (2001). Neonatal Screening for Galactosemia by Quantitative Analysis of Hexose Monophosphates Using Tandem Mass Spectrometry: A Retrospective Study. Clin Chem, 47 (8): 1364-72.
Ordookhani A, Hedayati M, Mirmiran P, Hajipour R, Azizi F (2000). High prevalence of neonatal hypothyroidism in Tehran. Iran J Endocrinol Metabol, 2 (4): 263-77.
Ko DH, Jun SH, Park KU, Song SH, Kim JQ, Song J (2011). Newborn screening for galactosemia by a second-tier multiplex enzyme assay using UPLC-MS/MS in dried blood spots. J Inherit Metab Dis, 34: 409-414.
Kingsmore SF, Lantos JD, Dinwiddie DL, Miller NA, Soden SE, Farrow EG, Saunders CJ (2012). Next-generation community genetics for low- and middle-income countries. Genome Med, 4(3): 25.
Groselj U, Tansek MZ, Smon A, Angelkova N, Anton D, Baric I, Djordjevic M, et al. (2014). Newborn screening in southeastern Europe. Mol Genet Metab, 113 (1-2): 42-5.
Vallian S (2009). Quantitative Bacterial Micro-Assay for Rapid Diagnosis of Galactosemia: Application in Galactosemia Neonatal Screening. Journal of Sciences, Islamic Republic of Iran, 20 (4): 319-23.
Agarwal M, Joshi K, Bhatia V, Gopalakrishnan V, Dabadghao P, Das V, Pandey A, Kumar M, Phadke SR (2015). Feasibility study of an outreach program of newborn screening in Uttar Pradesh. Indian J Pediatr, 82 (5): 427-32.
Gopalakrishnan V, Joshi K, Phadke S, Dabadghao P, Agarwal M, Das V, Jain S, Gambhir S, Gupta B, Pandey A, Kapoor D, Kumar M, Bhatia V (2014). Newborn screening for congenital hypothyroidism, galactosemia and biotinidase deficiency in Uttar Pradesh, India. Indian Pediatr, 51 (9): 701-5.
Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, et al. (2012). Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. Mol Genet Metab, 107 (3): 281-93.
Cuthbert C, Klapper H, Elsas L (2008). Diagnosis of inherited disorders of galactose metabolism. Curr Protoc Hum Genet, 17.5.
McCabe C (2009). What is cost–utility analysis? University of Leeds, England. Available from: http://www.bandolier.org.uk/painres/download/whatis/What_is_cost-util.pdf.
Lee J, Joseph R, Rajadurai VS (2008). Neonatal Screening–A Global Perspective. Ann Acad Med Singapore, 37 (12 Suppl): 1-2.
Fox-rushby J, Cairns J (2005). Economic Evaluation. Reprint. McGraw-Hill Education, UK.
Camelo Junior JS, Fernandes MI, Jorge SM, Maciel LM, Santos JL, Camargo AS Jr, Passador CS, Camelo SH (2011). [Newborn screening for galactosemia: a health economics evaluation]. Cad Saude Publica, 27 (4): 666-76.
Dhondt JL (2010). Expanded newborn screening: social and ethical issues. J Inherit Metab Dis, 33 (Suppl 2): S211-7.
Rastgar M (2010). Neonatal screening. Shiraz University of Medical Sciences, Iran. Available from: http://fhc.sums.ac.ir/files/gh-vagir/screening.pdf.
Central Bank of the Islamic Republic of Iran’s Web Site (2010). Available from: http://www.cbi.ir/exrates/rates_fa.aspx.
Tiwana SK, Rascati KL, Park H (2012). Cost-effectiveness of expanded newborn screening in Texas. Value Health, 15 (5): 613-21.
Camelo JS Jr, Fernandes MI, Maciel LM, Scrideli CA, Santos JL, et al. (2009). Galactosaemia in a Brazilian population: High incidence and cost–benefit analysis. J Inherit Metab Dis, 32: 1:S141-9.
Carroll AE, Downs SM (2006). Comprehensive Cost-Utility Analysis of Newborn Screening Strategies. Pediatrics, 117 (5): S287-95.
Norman R, Haas M, Wilcken B (2009). International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy, 89 (3): 252-60.
Wilson JMG, Jungner G (1968). Principles and practice of screening for disease. World Health Organization. Available from: http://apps.who.int/iris/bitstream/10665/37650/17/WHO_PHP_34.pdf.
Padilla CD, Lam ST (2008). Issues on Universal Screening for Galactosemia. Ann Acad Med Singapore, 37 (12): 39-3.
Clague A, Thomas A (2002). Neonatal biochemical screening for disease. Clin Chim Acta, 315 (1-2): 99-110.
Joshi SN, Bayoumi R (2012). Newborn Screening Program for Oman: The Time is here and Now. Oman Med J, 27 (5): 346-347.
Health Quality Ontario (2003). Neonatal screening of inborn errors of metabolism using tandem mass spectrometry: an evidence-based analysis. Ont Health Technol Assess Ser, 3 (3): 1-36.
Hsieh SH, Hsieh SL, Chien YH, Weng YC, Hsu KP, Chen CH, Tu CM, Wang Z, Lai F (2010). Newborn Screening Healthcare Information System Based on Service-Oriented Architecture. J Med Syst, 34 (4): 519-530.
| Files | ||
| Issue | Vol 46 No 1 (2017) | |
| Section | Short Communication(s) | |
| Keywords | ||
| Economic evaluation Cost-utility analysis Newborn screening Galactosemia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
